carbogen has been researched along with Urinary Bladder Neoplasms in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (17.65) | 18.2507 |
| 2000's | 7 (41.18) | 29.6817 |
| 2010's | 4 (23.53) | 24.3611 |
| 2020's | 3 (17.65) | 2.80 |
| Authors | Studies |
|---|---|
| Choudhury, A; Hoskin, PJ; Irlam, J; Lane, B; Mistry, H; Song, YP; Valentine, H; West, C; Yang, L | 1 |
| Aragaki, K; Choudhury, A; Dyrskjøt, L; Hoskin, PJ; Irlam-Jones, JJ; Khan, MT; Lane, B; McConkey, DJ; Pereira, RR; Valentine, HR; West, CML | 1 |
| Anzela, A; Azzopardi, M; Barrett, S; Buddle, N; Hooshmand, R; Knesl, M; Min, M; Notman, A; Vignarajah, DD; Wilson, J; Woolls, H | 1 |
| Alsner, J; Buffa, FM; Choudhury, A; Denley, H; Eustace, A; Harris, AL; Hoskin, PJ; Irlam, JJ; Taylor, J; West, CML; Yang, L | 1 |
| Agrawal, S; Choudhury, A; Denley, H; Eustace, A; Harris, AL; Hoskin, PJ; Irlam, JJ; Ord, JJ; Rojas, AM; Ryder, D; Taylor, J; West, CM | 1 |
| Betts, GN; Buffa, FM; Denley, H; Eustace, A; Harris, AL; Homer, JJ; Hoskin, PJ; Irlam, JJ; Kaanders, JH; Mani, N; Miller, CJ; Rojas, AM; Span, PN; Taylor, J; West, CM | 1 |
| Bentzen, SM; Hoskin, PJ; Motohashi, KJ; Rojas, AM; Saunders, MI | 1 |
| Hoskin, P; Rojas, A; Saunders, M | 1 |
| Bentzen, SM; Hoskin, PJ; Rojas, AM; Saunders, MI | 1 |
| Bussink, J; Kaanders, JH; van der Kogel, AJ | 1 |
| Hoskin, PJ; Phillips, H; Rojas, AM; Saunders, MI | 1 |
| Jouanneau, J; Kaffy, J; Pontikis, R; Thomas, CD; Volk, A; Walczak, C | 1 |
| Cladd, H; Goodchild, K; Hoskin, PJ; Phillips, H; Powell, ME; Rojas, A; Saunders, MI; Stratford, MR | 1 |
| Denekamp, J; Fowler, JF | 1 |
| Dische, S; Hoskin, PJ; Saunders, MI | 1 |
| Droller, MJ | 1 |
| Griffiths, JR; Howe, FA; Lofts, F; McIntyre, DJ; McSheehy, PM; Nicholson, G; Noordhuis, P; Peters, GJ; Price, NM; Rodrigues, LM; Smid, K; Stubbs, M; Wadsworth, P | 1 |
2 review(s) available for carbogen and Urinary Bladder Neoplasms
| Article | Year |
|---|---|
ARCON: a novel biology-based approach in radiotherapy.
Topics: Animals; Carbon Dioxide; Carcinoma; Cell Cycle; Cell Hypoxia; Clinical Trials as Topic; Dose Fractionation, Radiation; Head and Neck Neoplasms; Humans; Mammary Neoplasms, Animal; Mice; Niacinamide; Oxygen; Patient Selection; Radiation-Sensitizing Agents; Radiotherapy; Urinary Bladder Neoplasms | 2002 |
ARCON--current status: summary of a workshop on preclinical and clinical studies.
Topics: Animals; Carbon Dioxide; Cell Division; Cell Hypoxia; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Neoplasms; Neoplasms, Experimental; Niacinamide; Oxygen; Oxygen Consumption; Radiation-Sensitizing Agents; Radiobiology; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Regional Blood Flow; Urinary Bladder Neoplasms | 1997 |
10 trial(s) available for carbogen and Urinary Bladder Neoplasms
| Article | Year |
|---|---|
Long-Term Outcomes of Radical Radiation Therapy with Hypoxia Modification with Biomarker Discovery for Stratification: 10-Year Update of the BCON (Bladder Carbogen Nicotinamide) Phase 3 Randomized Trial (ISRCTN45938399).
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carbon Dioxide; Confidence Intervals; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Middle Aged; Necrosis; Niacinamide; Oxygen; Radiation-Sensitizing Agents; Regression Analysis; Survival Rate; Time Factors; Treatment Outcome; Tumor Hypoxia; Urinary Bladder Neoplasms | 2021 |
A miRNA signature predicts benefit from addition of hypoxia-modifying therapy to radiation treatment in invasive bladder cancer.
Topics: Biomarkers, Tumor; Carbon Dioxide; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemoradiotherapy; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Niacinamide; Oligonucleotide Array Sequence Analysis; Oxygen; Prognosis; Survival Analysis; Urinary Bladder Neoplasms | 2021 |
Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial.
Topics: Aged; Aged, 80 and over; Carbon Dioxide; Carbonic Anhydrase IV; Cell Hypoxia; Female; Glucose Transporter Type 1; Humans; Male; Middle Aged; Necrosis; Niacinamide; Oxygen; Risk; Urinary Bladder Neoplasms | 2013 |
A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer.
Topics: Carbon Dioxide; Cell Hypoxia; Female; Gene Expression Regulation, Neoplastic; Humans; Laryngeal Neoplasms; Male; Niacinamide; Oxygen; Radiation-Sensitizing Agents; Urinary Bladder Neoplasms | 2013 |
Carbogen and nicotinamide in locally advanced bladder cancer: early results of a phase-III randomized trial.
Topics: Aged; Aged, 80 and over; Carbon Dioxide; Carcinoma, Transitional Cell; Dose Fractionation, Radiation; Female; Humans; Male; Middle Aged; Neoplasm Invasiveness; Niacinamide; Oxygen; Radiation-Sensitizing Agents; Radiotherapy Dosage; Treatment Outcome; Urinary Bladder Neoplasms | 2009 |
Accelerated radiotherapy, carbogen, and nicotinamide (ARCON) in the treatment of advanced bladder cancer: mature results of a Phase II nonrandomized study.
Topics: Adult; Aged; Aged, 80 and over; Carbon Dioxide; Carcinoma in Situ; Cystectomy; Dose Fractionation, Radiation; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasm Staging; Niacinamide; Oxygen; Radiation-Sensitizing Agents; Remission Induction; Survival Rate; Urinary Bladder Neoplasms | 2009 |
Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma.
Topics: Aged; Aged, 80 and over; Carbon Dioxide; Cystectomy; Female; Humans; Male; Middle Aged; Neoplasm Staging; Niacinamide; Oxygen; Radiation-Sensitizing Agents; Urinary Bladder Neoplasms | 2010 |
Acute and late morbidity in the treatment of advanced bladder carcinoma with accelerated radiotherapy, carbogen, and nicotinamide.
Topics: Adult; Aged; Aged, 80 and over; Carbon Dioxide; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cell Hypoxia; Combined Modality Therapy; Disease-Free Survival; Humans; Middle Aged; Niacinamide; Oxygen; Radiotherapy, High-Energy; Survival Rate; Urinary Bladder Neoplasms | 2005 |
Carbogen and nicotinamide in the treatment of bladder cancer with radical radiotherapy.
Topics: Aged; Carbon Dioxide; Carcinoma; Chemotherapy, Adjuvant; Cohort Studies; Female; Humans; Male; Middle Aged; Niacinamide; Oxygen; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Treatment Outcome; Urinary Bladder Neoplasms; Urination | 1997 |
Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma: hyperbaric oxygen, misonidazole, and accelerated radiotherapy, carbogen, and nicotinamide.
Topics: Adult; Aged; Carbon Dioxide; Humans; Hyperbaric Oxygenation; Middle Aged; Misonidazole; Niacinamide; Oxygen; Radiation-Sensitizing Agents; Radiotherapy Dosage; Urinary Bladder Neoplasms | 1999 |
5 other study(ies) available for carbogen and Urinary Bladder Neoplasms
| Article | Year |
|---|---|
Concurrent carbogen and nicotinamide with radiation therapy in muscle invasive bladder cancer: A report on feasibility in the Australian setting.
Topics: Aged; Australia; Carbon Dioxide; Feasibility Studies; Humans; Muscles; Neoplasm Recurrence, Local; Niacinamide; Oxygen; Urinary Bladder Neoplasms | 2021 |
A Gene Signature for Selecting Benefit from Hypoxia Modification of Radiotherapy for High-Risk Bladder Cancer Patients.
Topics: Aged; Carbon Dioxide; Clinical Trials, Phase III as Topic; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Hypoxia; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Oxygen; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Urinary Bladder Neoplasms | 2017 |
Early effects of combretastatin A4 phosphate assessed by anatomic and carbogen-based functional magnetic resonance imaging on rat bladder tumors implanted in nude mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carbon Dioxide; Contrast Media; Magnetic Resonance Imaging; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Oxygen; Radiation-Sensitizing Agents; Rats; Stilbenes; Time Factors; Urinary Bladder Neoplasms | 2006 |
Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma: hyperbaric oxygen, misonidazole, and accelerated radiotherapy, carbogen and nicotinamide.
Topics: Carbon Dioxide; Humans; Hyperbaric Oxygenation; Misonidazole; Niacinamide; Oxygen; Radiation-Sensitizing Agents; Urinary Bladder Neoplasms | 2000 |
Issues of normal tissue toxicity in patient and animal studies--effect of carbogen breathing in rats after 5-fluorouracil treatment.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Biological Availability; Bone Marrow; Carbon Dioxide; Carcinoma, Transitional Cell; Colonic Neoplasms; Colorectal Neoplasms; Combined Modality Therapy; Fatal Outcome; Female; Fluorine Radioisotopes; Fluorodeoxyuridylate; Fluorouracil; Humans; Intestine, Small; Leucovorin; Liver; Liver Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasms, Multiple Primary; Oxygen; Rats; Rats, Inbred WF; Sigmoid Neoplasms; Tomography, X-Ray Computed; Ultrasonography; Urinary Bladder Neoplasms | 2001 |